First Report on the Prevalence of Bacteria in Cystic Fibrosis Patients (CF) in a Tertiary Care Center in Saudi Arabia

Overview

Journal Int J Pediatr Adolesc Med

Date 2022 Jun 6

PMID 35663786

Authors

Hanaa Banjar

Afrah Ghawi

Ibrahim AlMogarri

Sami Alhaider

Hanan Alomran

Abdullah Hejazi

Abdulrahaman Alfadhel

Sharouk Khanjar

Mais AlAshgar

Alaa Alghazzi

Lama Abanemai

Areej AlFattani

Affiliations

Soon will be listed here.

Abstract

Introduction: Bacterial infections in CF patients are common and start early in life. The prognosis of the disease is substantially dependent on chronic respiratory infection and inflammation. (PA) infection or chronic colonization have been established to cause a chronic decline in pulmonary function (PFT), and/or increase CF mortality.

Objectives: To obtain the prevalence of all bacterial pathogens in our CF patients and assess their evolution over time.

Method: A retrospective review of 327 patients with confirmed CF of all age groups, who had respiratory culture samples at the first visit and on a regular follow-up between January 1, 1990 and December 2018, was conducted.

Results: A total of 327 patients had a respiratory culture obtained at presentation. Two hundred and sixteen (66%) of 327 patients are alive, while 111 (34%) have died. Respiratory cultures were taken from nasopharyngeal aspiration (NPA) in 199 patients (61%), tracheal aspirate in 9 (3%), bronchoalveolar lavage (BAL)in one (0.29%), and in 124 patients (38%), sputum was induced. The eastern province contributed to the highest number of patients (122, 37.7%). There is a persistent increase in the prevalence of the common bacteria over the follow-up period of 7 years, namely and all culture types.Comparing cultures from the first and last follow-up visits, there was an increase in the prevalence of all () cultures from 120 (34%) to 137 (53%), and a decrease in the prevalence of () and () during the same follow-up period.

Conclusion: There is a progressive increase in the number of patients with the most pathogenic types of bacteria because of the advanced age at presentation. As more adult patients are enrolled, there is a need for improved awareness regarding the early eradication of pathogenic bacteria to prevent progressive pulmonary damage.

Citing Articles

Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients.

Rastegar-Kashkouli A, Khaledi A, Moammer F, Ghenaatpisheh Sanani M, Heidari M, Foroughi Eghbal A Eurasian J Med. 2024; 56(3):189-198.

PMID: 39655837 PMC: 11535318. DOI: 10.5152/eurasianjmed.2024.23302.

Molecular identification and biofilm formation of aerobic and anaerobic coinfection bacterial isolated from cystic fibrosis patients in southwest Iran from 2014 to 2022.

Moogahi S, Beni F, Hashemzadeh M, Asareh Zadegan Dezfuli A Mol Biol Rep. 2023; 50(10):8225-8235.

PMID: 37566205 DOI: 10.1007/s11033-023-08724-7.

References

Konstan M, Hilliard K, Norvell T, Berger M . Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994; 150(2):448-54. DOI: 10.1164/ajrccm.150.2.8049828. View

DORING G, Hoiby N . Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983; 42(1):197-201. PMC: 264542. DOI: 10.1128/iai.42.1.197-201.1983. View

Brett M, Simmonds E, Ghoneim A, Littlewood J . The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child. 1992; 67(9):1086-8. PMC: 1793633. DOI: 10.1136/adc.67.9.1086. View

Banjar H, Angyalosi G . The road for survival improvement of cystic fibrosis patients in Arab countries. Int J Pediatr Adolesc Med. 2019; 2(2):47-58. PMC: 6372404. DOI: 10.1016/j.ijpam.2015.05.006. View

Saiman L, Siegel J . Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003; 24(5 Suppl):S6-52. DOI: 10.1086/503485. View

DORING G, Conway S, Heijerman H, Hodson M, Hoiby N, Smyth A . Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000; 16(4):749-67. DOI: 10.1034/j.1399-3003.2000.16d30.x. View

Ratjen F, Comes G, Paul K, Posselt H, Wagner T, Harms K . Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol. 2001; 31(1):13-6. DOI: 10.1002/1099-0496(200101)31:1<13::aid-ppul1001>3.0.co;2-n. View

De Boeck K, Alifier M, Vandeputte S . Sputum induction in young cystic fibrosis patients. Eur Respir J. 2000; 16(1):91-4. DOI: 10.1034/j.1399-3003.2000.16a16.x. View

Koch C, McKenzie S, Kaplowitz H, Hodson M, Harms H, Navarro J . International practice patterns by age and severity of lung disease in cystic fibrosis: data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatr Pulmonol. 1997; 24(2):147-54; discussion 159-61. DOI: 10.1002/(sici)1099-0496(199708)24:2<147::aid-ppul15>3.0.co;2-2. View

10.

Burns J, Gibson R, McNamara S, Yim D, Emerson J, Rosenfeld M . Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001; 183(3):444-52. DOI: 10.1086/318075. View

11.

Rosenfeld M, Gibson R, McNamara S, Emerson J, Burns J, Castile R . Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001; 32(5):356-66. DOI: 10.1002/ppul.1144. View

12.

Johansen H, Hoiby N . Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax. 1992; 47(2):109-11. PMC: 463585. DOI: 10.1136/thx.47.2.109. View

13.

Kahl B, Herrmann M, Everding A, Koch H, Becker K, Harms E . Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis. 1998; 177(4):1023-9. DOI: 10.1086/515238. View

14.

Ratjen F, Doring G . Cystic fibrosis. Lancet. 2003; 361(9358):681-9. DOI: 10.1016/S0140-6736(03)12567-6. View

15.

Burns J, Emerson J, Stapp J, Yim D, Krzewinski J, Louden L . Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998; 27(1):158-63. DOI: 10.1086/514631. View

16.

Petersen N, Hoiby N, Mordhorst C, Lind K, FLENSBORG E, Bruun B . Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981; 70(5):623-8. DOI: 10.1111/j.1651-2227.1981.tb05757.x. View

17.

Dakin C, Numa A, Wang H, Morton J, Vertzyas C, Henry R . Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 2002; 165(7):904-10. DOI: 10.1164/ajrccm.165.7.2010139. View

18.

West S, Zeng L, Lee B, Kosorok M, Laxova A, Rock M . Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002; 287(22):2958-67. DOI: 10.1001/jama.287.22.2958. View

19.

Granchelli A, Adler F, Keogh R, Kartsonaki C, Cox D, Liou T . Microbial Interactions in the Cystic Fibrosis Airway. J Clin Microbiol. 2018; 56(8). PMC: 6062800. DOI: 10.1128/JCM.00354-18. View

20.

Banjar H, Al-Qahtani H, Yasin W, Al-Wgait W, Al-Amer H, Raja R . The first report of Methicillin-resistant (MRSA) in cystic fibrosis (CF) patients in Saudi Arabia. Int J Pediatr Adolesc Med. 2020; 7(4):186-190. PMC: 7729253. DOI: 10.1016/j.ijpam.2019.10.005. View